While investigations were in progress he was treated with broad spectrum antibiotics and vitamin K, which corrected the coagulopathy. There was an initial improvement, the serum bilirubin falling to 1000 ,umol/l and AST to 40 IU/1 but the downward trend was not sustained. After three weeks the serum bilirubin was static at 900-1000 jimol/l and the AST had risen to 505 IU/1 with an alkaline phosphatase of 351 IU/l. No new clinical signs emerged (that is, he continued to have painless jaundice together with pale stools and dark urine) and specifically there were no signs of liver failure. His appetite was poor and he did not regain his lost weight. He continued to receive parenteral vitamin K to correct his prothrombin time. His albumin fell to 33 g/l. Plugged liver biopsy was performed under ultrasound guidance. Portal tracts were moderately extending by an increase in fibrous tissue, which was expanding into the adjacent hepatic parenchyma. The presence of increased amounts of copper and copper associated protein in hepatocytes in Rappaport Zone 1 was confirmed by rhodanine and orceine staining, respectively. Moderate hyperplasia of hepatic parenchymal cells with ballooning of cytoplasm, prominent diffuse intracanalicular cholestasis, and sinusoidal dilatation (Fig 1) was present throughout all zones. Kupffer cells were prominent and hyperplastic. In some regions of the parenchyma there was regional collapse of the reticular architecture suggesting previous focal confluent necrosis. Increased deposition of iron within reticuloendothelial cells, including Kupffer cells, was confirmed by Perl's staining. These appearances were strongly in favour of chronic cholestasis associated with longterm haemochromatosis secondary to haemolysis.
Before liver biopsy, an exchange transfusion was carried out. There was a dramatic normal without vitamin K. His weight, which had dropped by 5 kg to the 25th centile over the three months of his acute illness, began to rise and had returned, without nutritional supplementation, to the 75th centile after nine months. Liver biopsy at eight months showed histological recovery.
About one year after initial presentation, after a period of erratic attendance at hospital, his haemoglobin S concentration rose to 56%. His original symptoms of fever, severe jaundice, right upper quadrant pain associated with dark urine, pale stools, and hepatomegaly returned. His only treatment was prophylactic penicillin V and folic acid. Biochemical profile showed raised bilirubin at 736 g,mol/1; AST 73 IU/1; alkaline phosphatase 391 IU/1. The prothrombin time was prolonged at 18 seconds but the haemoglobin was stable at 9.6 gfdl.
Although his AST continued to rise, reaching a peak of 430 IU/1, again this relapse rapidly responded to exchange transfusion (Fig 2) . He continues, nearly three years after presentation to require regular exchange transfusions to control the hyperbilirubinaemia. patient whose symptoms persisted for three months and could only be controlled by intensive exchange transfusion every two weeks. Indeed his symptoms returned when, after erratic attendance, his haemoglobin S concentration rose to 56%. Our patient also differs from the more commonly observed hepatic crisis in that he had no other features of an acute sickle cell crisis and in particular no pain or evidence of increased haemolysis as shown by a stable haemoglobin and reticulocyte count during such episodes. The duration and slow onset of the extreme hyperbilirubinaemia and the absence of typical features of painful sickle cell crises together make it much more probable that this represented chronic intrahepatic cholestasis rather than recurrent episodes of sickle cell crisis.
Discussion
A distinct clinical presentation is that of sickle cell intrahepatic cholestasis, which is a syndrome defined by characteristic histological features: intracanalicular cholestasis, sinusoidal dilatation, Kupffer cell hyperplasia, and debris.l1 The absence of sickled red blood cells in biopsy specimens from patients with sickle cell disease may be explained by the accepted practice of performing exchange transfusion before invasive procedures. Some previous reports of intrahepatic cholestasis were associated with a high death rate, (seven of the first eight reported cases), the cause of death being fulminant hepatic failure or bleeding diathesis, or both.2 4 10 The characteristic histological pattern was described on examination of necropsy specimens. Partial exchange transfusion was first used in this situation in 1980 and it proved to be a life-saving intervention. Signs of liver failure regressed in 48 hours and biochemical resolution was almost complete within one week. 10 In contrast with the above severe clinical picture a benign course of extreme hyperbilirubinaemia has been reported.5 11 In a group of children, who had few signs and symptoms and unremarkable liver enzyme activities, bilirubin values ranging from 347 to 979 ,umol/l were recorded. In all, the condition was self limiting with return to steady state values within two to eight weeks and liver function tests remained normal on longterm follow up." Biopsy was not performed in any of these cases so histological proof of a similar process is not available. A benign self limiting cholestatic syndrome has also been seen in association with oxymethalone administration, phenothiazine ingestion, and pregnancy in sickle cell patients. 5 In the presence of typical histology and having excluded other possible secondary causes,8 9 12 the hepatic dysfunction seen in this patient seems to be caused by sickle cell intrahepatic cholestasis. The clinical, biochemical, and histological recovery in response to intensive exchange transfusion regimen supports this, as does the relapse in conjunction with a rising haemoglobin S concentration.
We have described an unusual case of prolonged intrahepatic cholestasis in a patient with sickle cell disease characterised by extreme hyperbilirubinaemia. We believe that it is important to recognise this condition as successful treatment requires intensive and maintained exchange transfusion to return liver function to steady state. This sets it apart from other causes of pronounced hyperbilirubinaemia in sickle cell disease, which are transient and may be either benign, usually in children, or associated with fulminant hepatic failure and early death.
